Improved Drug Regimens for TB likely to reduce treatment time

Improved Drug Regimens for TB likely to reduce treatment time

Subject : Science and Tech

Section: HEALTH

Context:

• The Union World Conference on Lung Health 2023 showcased optimism in the fight against tuberculosis (TB) with the introduction of four new improved drug regimens.

More about News

• The primary focus was on reducing the treatment time for drug-resistant tuberculosis, which is crucial due to the long duration of conventional treatments leading to patient intolerance and non-compliance.
• The duration of TB treatment and the associated drug toxicity contribute to the development of drug-resistant TB, a serious concern in global TB control efforts.
• Previous advances in TB care have been limited, with the absence of a viable vaccine for prevention, making news of effective treatments particularly significant.

Key Highlights:

• New Drug Regimens:
  • Four improved drug regimens were presented at the conference, demonstrating the potential to reduce treatment time for drug-resistant TB by up to two-thirds.
  • These regimens offer hope for more effective and tolerable treatments, addressing the challenge of patient non-compliance and drug resistance.
• Positive Outcomes:
  • Three regimens achieved favorable outcomes in 85-90% of participants for the treatment of multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB).
  • A fourth regimen showed a strong treatment response at 85.6%, providing an alternative for individuals unable to tolerate specific drugs.
  • The regimens demonstrated similar efficacy and safety to conventional treatments but significantly reduced treatment time.
• Research Impact:
  • Over 750 participants from 11 sites, 7 countries, and 4 continents were involved in the study, funded by Unitaid, highlighting a collaborative global effort.
  • Combining antibiotics in new ways through research led by organizations such as Médecins Sans Frontières, Partners in Health, and Interactive Research and Development showed promising results.
• Global Significance:
  • The findings represent a significant step in addressing issues related to access to and affordability of quality TB care, offering hope to vulnerable populations globally.
  • The urgency of continued research and innovation, along with accountability of private companies receiving public funds, was emphasized.
• Multi-pronged Approach:
  • Experts emphasize a multi-pronged approach to tackle TB, addressing not only treatment regimens but also improving case detection.
  • Advances in diagnostic tools, including AI-assisted tests and portable, battery-operated tests, were discussed as essential for early detection and prevention.
• Future Directions:
  • Calls for a stronger commitment to developing a TB vaccine were made, highlighting the need for global efforts to eliminate the disease.
  • Phasing out old diagnostic tools like smear microscopy in favor of rapid molecular tests was emphasized to narrow the diagnostic gap.